Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06808230 · ClinicalTrials.gov registry record · NA
Cocoa Extract for Migraine Trial
A NA study of Migraine, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 114
- Enrollment target
- 1
- Study location
NCT06808230: Recruiting NA study of Migraine, sponsored by Brigham and Women's Hospital.
NCT06808230 is a NA study of Migraine that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 114 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06808230, a NA study of Migraine, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 114 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess the feasibility of recruitment and adherence to a high-dose cocoa extract supplement in individuals diagnosed with episodic migraine. The main questions it aims to answer are: * Will we be able to enroll 114 participants during the recruitment period? * Will participants take study pills daily during the pill-taking period? Researchers will compare two doses of cocoa extract to placebo to determine the acceptability of higher doses of cocoa extract supplementation in this patient population. Participants will be asked to: * Provide two urine samples * Complete daily questionnaires * Take four study pills a day for 12 weeks
Primary Outcome
We will be able to recruit and randomize 114 eligible individuals
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Cocoa extract
- DIETARY_SUPPLEMENT Cocoa extract placebo
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2026-12-01 |
| Phase | NA |
What NCT06808230 shows while recruiting
NCT06808230 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Cocoa extract is the first listed.
NCT06808230 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06808230 about?
NCT06808230 is a clinical study titled "Cocoa Extract for Migraine Trial". The goal of this clinical trial is to assess the feasibility of recruitment and adherence to a high-dose cocoa extract supplement in individuals diagnosed with episodic migraine. The main questions it aims to answer are: * Will we be able to enroll 114 participants during the recruitment period? * ...
What is the current status of trial NCT06808230?
This trial is currently recruiting. It is a NA study. The enrollment target is 114 participants. The study started on 2025-06-23. Estimated completion is 2026-12-01.
What conditions does trial NCT06808230 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06808230?
The interventions under investigation include: Cocoa extract (DIETARY_SUPPLEMENT), Cocoa extract placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06808230?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06808230 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06808230's enrollment target sits among peer trials
114 55th of 102 higher than 48 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Migraine in Adolescents
RECRUITING · NA
-
Mind Body Balance for Pediatric Migraine
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI